The Canadian Rett Syndrome Coalition - comprising the Rett Syndrome Society of British Columbia (RSSBC), Rett Syndrome Society of Alberta (RSSA), Saskatchewan Rett Syndrome Association (SRSA), ...
The Big Pharma’s window to take up exclusive rights to Taysha’s lead asset, dubbed TSHA-102, has officially closed, according ...
Taysha Gene Therapies shares fall after regaining full rights to Rett syndrome drug TSHA-102 and finalizing FDA alignment for ...
The 2022 Option Agreement between Astellas and Taysha has expiredRegaining full rights to TSHA-102 Rett syndrome program enables Taysha to focus ...
3monon MSN
A-Z of Rett Syndrome
BENGALURU: Awareness about rare diseases can sometimes prevent serious conditions from being overlooked. One such condition ...
5d
How Regaining Full Rights to Rett Syndrome Gene Therapy Has Changed Taysha (TSHA)’s Investment Story
Recently, Taysha Gene Therapies announced it has regained full rights to its lead gene therapy candidate TSHA-102 for Rett syndrome after the expiration of an option agreement with Astellas, following ...
Taysha’s TSHA-102 shows 100% response in Rett, with FDA Breakthrough status and strong trial design supporting BLA hopes. Read why TSHA stock is a buy.
New discoveries about the severe developmental disorder known as Rett syndrome could open the door to better treatments for the devastating, life-shortening condition. Scientists investigating the ...
Rett syndrome is a rare disorder linked to autism that affects brain development. Microglia, the resident immune cells of the central nervous system, have been implicated in the development of Rett ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback